Regulation of the development of allodynia by intrathecally administered P2 purinoceptor agonists and antagonists in mice.
Effects of agonists and antagonists of P2X-purinoceptors on the regulation of the development of allodynia were examined in mice; the drugs were administered intrathecally to the spinal cord. Suramin (5, 10 microg) and pyridoxalphosphate-6-azophenyl-2', 4'-disulfonic acid (PPADS), antagonists of P2X receptors, inhibited prostaglandin (PG) E(2)-induced allodynia. PPADS did not block glutamate-induced allodynia. alpha,beta-Methylene ATP (alpha, beta-meATP), an agonist of P2X receptor, elicited allodynia. alpha, beta-me ATP-induced allodynia was blocked by co-administration of alpha,beta-meATP with PPADS, MK 801 or N(omega)-nitro-L-arginine methyl ester (L-NAME). Suramin at higher doses (20, 40 microg) induced allodynia, which was inhibited by MK 801 or L-NAME. These results suggest that ATP P2X receptors in the spinal cord are involved in the regulation of tactile allodynia. Glutamate receptor and nitric oxide systems play an important role in the development of allodynia produced by alpha,beta-meATP and suramin.
Fukuhara
N
N
Department of Orthodontics, Hiroshima University Faculty of Dentistry, 734-8553, Hiroshima, Japan.
Imai
Y
Y
Sakakibara
A
A
Morita
K
K
Kitayama
S
S
Tanne
K
K
Dohi
T
T
D000255:Adenosine Triphosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D015232:Dinoprostone / Q000008:administration & dosage; D016291:Dizocilpine Maleate / Q000008:administration & dosage; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D018696:Neuroprotective Agents / Q000008:administration & dosage; D010120:Oxytocics / Q000008:administration & dosage; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011732:Pyridoxal Phosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013498:Suramin / Q000008:administration & dosage
D018696:Neuroprotective Agents; D010120:Oxytocics; D010975:Platelet Aggregation Inhibitors; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D013498:Suramin; D016291:Dizocilpine Maleate; D000255:Adenosine Triphosphate; D015232:Dinoprostone; C002630:alpha,beta-methyleneadenosine 5'-triphosphate